Literature DB >> 22532039

[Immunological graft rejection after autologous contralateral keratoplasty].

S Schmidt1, M P Holzer, R Khoramnia, G U Auffarth.   

Abstract

Autologous keratoplasty from an amblyopic eye to the fellow oculus ultimus is a rarely used procedure. This is due to the relatively uncommon constellation of pathology. The following article reports the case of a graft rejection after autologous keratoplasty, while the homologous graft on the amblyopic fellow eye remained clear.

Mesh:

Substances:

Year:  2012        PMID: 22532039     DOI: 10.1007/s00347-012-2560-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  6 in total

1.  Corneal autografts: are the theoretical advantages achieved in practice?

Authors:  A R Pearson; J H Sanford-Smith
Journal:  Eye (Lond)       Date:  2000-02       Impact factor: 3.775

2.  [Progressive corneal opacity after autologous keratoplasty].

Authors:  V Witte; S Knappe; R Guthoff
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

3.  CORNEAL AUTOGRAFTS, IPSILATERAL AND CONTRALATERAL.

Authors:  T GUNDERSEN; A F CALNAN
Journal:  Arch Ophthalmol       Date:  1965-02

Review 4.  The immunobiology of corneal transplantation.

Authors:  Keryn A Williams; Douglas J Coster
Journal:  Transplantation       Date:  2007-10-15       Impact factor: 4.939

5.  Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty.

Authors:  Daniel Böhringer; Thomas Reinhard; René J Duquesnoy; Stefan Böhringer; Jürgen Enczmann; Peter Lange; Frans Claas; Rainer Sundmacher
Journal:  Transplantation       Date:  2004-02-15       Impact factor: 4.939

6.  Operational post-keratopasty graft tolerance due to differential HLAMatchmaker matching.

Authors:  Daniel Böhringer; Frieder Daub; Johannes Schwartzkopff; Philip Maier; Florian Birnbaum; Rainer Sundmacher; Thomas Reinhard
Journal:  Mol Vis       Date:  2010-11-11       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.